Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in adolescents with moderate to severe plaque psoriasis
2020-001724-34Phase 2
- Sponsor
- UCB
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bimekizumab in plaque psoriasis (2 arms), sponsored by UCB. Primary endpoint: Plasma concentration of bimekizumab at Week 0.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2020-001724-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001724-34.